| Business Summary | | CPC
of
America,
Inc.
is
engaged
in
the
business
of
developing
and
acquiring
cardiology
therapeutic
and
disposable
devices
and
products
as
well
as
the
manufacture
and
distribution
of
these
devices
and
products
for
the
diagnosis
and
treatment
of
coronary
artery
disease.
To
date,
the
Company
has
developed
the
CPCA
2000
counterpulsation
devices
and
acquired
a
controlling
interest
in
the
MedClose
internal
puncture
closing
device
and
technique.
The
Company's
first
product,
the
CPCA
2000
counterpulsation
unit,
is
a
non-invasive,
atraumatic
and
non-toxic
method
of
treating
certain
coronary
disease
states.
MedClose
is
an
internal
puncture
closure
device
and
technique,
which
utilizes
a
human
glue
deployment
to
close
puncture
wounds
following
surgery.
Both
the
CPCA
2000
and
Medclose
are
in
the
development
stage,
and
neither
has
been
approved
for
sale
by
the
FDA. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CPC
of
America,
Inc.
intends
to
manufacture
and
distribute
external
counterpulsation
devices
for
the
treatment
of
coronary
artery
disease
and
to
provide
counterpulsation
treatment
through
Company-owned
and
joint-venture
clinical
facilities.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
rose
1%
to
$670
thousand.
Higher
loss
reflects
increased
general
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Rod Shipman, 49 Pres,
CEO, Sec., Director | $195K | $521K | Rafe Cohen, 52 Treasurer | -- | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|